Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses TVTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TVTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Dube | $854,250 | $0 | $3,314,520 | $3,309,384 | $964,125 | $0 | $14,872 | $8,457,151 |
| President, Chief Executive Officer and Director | ||||||||
| Jula Inrig | 568,084 | 0 | 757,020 | 1,272,840 | 429,000 | 0 | 14,688 | 3,041,632 |
| Chief Medical Officer | ||||||||
| Peter Heerma | 527,917 | 0 | 583,110 | 738,247 | 397,500 | 0 | 14,977 | 2,261,751 |
| Chief Commercial Officer | ||||||||
| William Rote | 522,334 | 0 | 583,110 | 738,247 | 393,000 | 0 | 19,774 | 2,256,465 |
| Chief Research Officer | ||||||||
| Christopher Cline | 522,917 | 0 | 583,110 | 738,247 | 393,750 | 0 | 12,890 | 2,250,914 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Eric Dube | $8,457,151 | $5,204,877 | $7,574,959 | +3,252,274 |
| Jula Inrig | 3,041,632 | 1,681,277 | 2,001,539 | +1,360,355 |
| Peter Heerma | 2,261,751 | 1,513,360 | 2,003,914 | +748,391 |
| William Rote | 2,256,465 | 1,516,646 | 2,053,099 | +739,819 |
| Christopher Cline | 2,250,914 | 1,501,520 | 1,971,490 | +749,394 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Roy Baynes | Director | 2026-04-06 | D | 10,000 | $33 | $330,000 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-06 | A | 10,000 | 27 | 265,200 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-06 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 5,226 | 42 | 217,506 | Common, open-market sale | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 7,215 | 42 | 302,516 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-04-13 | A | 14,000 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | A | 20,000 | 18 | 359,200 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-04-13 | D | 7,215 | 42 | 302,516 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-04-13 | D | 9 | 41 | 370 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | A | 14,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Dube | Director | 2026-04-13 | D | 20 | 43 | 853 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-04-13 | A | 14,000 | 0 | 0 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-04-13 | D | 1,018 | 43 | 43,377 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | 2026-04-13 | A | 14,000 | 0 | 0 | Common | Form 4 ↗ |
| William Rote | Chief Research Officer | 2026-04-13 | A | 14,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Dube | Director | 2026-04-13 | A | 64,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Dube | Director | 2026-04-13 | D | 7,165 | 42 | 299,139 | Common, open-market sale | Form 4 ↗ |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | 2026-04-13 | D | 7,215 | 42 | 302,516 | Common | Form 4 ↗ |
| Eric Dube | Director | 2026-04-13 | D | 56,815 | 41 | 2,329,983 | Common, open-market sale | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-04-13 | D | 7,239 | 42 | 303,523 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | A | 10,000 | 19 | 190,800 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 1,559 | 43 | 66,304 | Common, open-market sale | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | A | 7,500 | 15 | 115,950 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-04-13 | D | 37,500 | 41 | 1,540,125 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-04-13 | D | 1,014 | 43 | 43,207 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-04-13 | D | 65 | 29 | 1,875 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 6,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | D | 21,977 | 41 | 902,595 | Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | A | 2,500 | 22 | 56,000 | Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | D | 6,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Lyons | Director | 2026-04-14 | A | 8,000 | 16 | 130,640 | Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | A | 6,500 | 20 | 132,990 | Common | Form 4 ↗ |
| Gary Lyons | Director | 2026-04-14 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 4,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | A | 9,000 | 15 | 138,870 | Common | Form 4 ↗ |
| Gary Lyons | Director | 2026-04-14 | D | 8,000 | 41 | 328,560 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | A | 6,750 | 17 | 115,493 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | A | 8,000 | 18 | 143,520 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | A | 4,500 | 18 | 82,215 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 6,750 | 42 | 284,310 | Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | A | 6,250 | 9 | 55,813 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 26,000 | 41 | 1,067,820 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | D | 4,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-04-14 | A | 4,500 | 21 | 96,210 | Common | Form 4 ↗ |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2026-04-14 | D | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Rote | Chief Research Officer | 2026-04-22 | D | 9,100 | 39 | 355,719 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-01 | D | 9,750 | 44 | 431,145 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-01 | D | 9,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-01 | A | 9,750 | 7 | 66,495 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-05-04 | A | 8,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | A | 4,250 | 0 | 0 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | A | 8,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Rote | Chief Research Officer | 2026-05-04 | D | 2,763 | 44 | 121,434 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | A | 20,000 | 18 | 359,200 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | A | 4,250 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | D | 2,174 | 47 | 101,417 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | A | 8,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | D | 20,000 | 45 | 900,000 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | D | 4,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | 2026-05-04 | A | 4,250 | 0 | 0 | Common | Form 4 ↗ |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | 2026-05-04 | D | 4,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dube | Director | 2026-05-04 | D | 22,500 | 44 | 988,875 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-05-04 | D | 310 | 44 | 13,625 | Common | Form 4 ↗ |
| William Rote | Chief Research Officer | 2026-05-04 | D | 4,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | D | 20,000 | 45 | 900,000 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | D | 2,076 | 44 | 91,240 | Common | Form 4 ↗ |
| Elizabeth E. Reed | Chief Legal Officer and GC | 2026-05-04 | D | 4,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dube | Director | 2026-05-04 | A | 22,500 | 0 | 0 | Common | Form 4 ↗ |
| Eric Dube | Director | 2026-05-04 | D | 22,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | D | 2,174 | 47 | 101,417 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-05-04 | D | 2,181 | 47 | 101,744 | Common | Form 4 ↗ |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | 2026-05-04 | D | 2,174 | 47 | 101,417 | Common | Form 4 ↗ |
| Jeffrey Meckler | Director | 2026-05-04 | A | 8,000 | 16 | 130,640 | Common | Form 4 ↗ |
| Jeffrey Meckler | Director | 2026-05-04 | D | 8,000 | 45 | 360,000 | Common | Form 4 ↗ |
| Jeffrey Meckler | Director | 2026-05-04 | D | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Rote | Chief Research Officer | 2026-05-04 | A | 4,250 | 0 | 0 | Common | Form 4 ↗ |
| William Rote | Chief Research Officer | 2026-05-04 | A | 8,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | A | 20,000 | 22 | 448,000 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-05-04 | D | 311 | 44 | 13,668 | Common | Form 4 ↗ |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | 2026-05-04 | A | 8,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dube | Director | 2026-05-04 | A | 45,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-05-04 | A | 4,250 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Cline | CHIEF FINANCIAL OFFICER | 2026-05-04 | D | 4,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-05 | A | 4,500 | 18 | 82,215 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-05 | D | 4,500 | 47 | 209,925 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-05 | D | 4,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-05-15 | D | 3,250 | 43 | 141,343 | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Bruhn | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John A. Orwin | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Brinkley Ruth Williams | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Sandra Poole | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Gary Lyons | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Lyons | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Meckler | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Poole | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Brinkley Ruth Williams | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Meckler | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Bruhn | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-05-19 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| John A. Orwin | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-05-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-06-12 | D | 4,500 | 50 | 225,000 | Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-12 | D | 10,000 | 50 | 500,747 | Common, open-market sale | Form 4 ↗ |
| Roy Baynes | Director | 2026-06-12 | D | 4,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-12 | A | 10,000 | 27 | 265,200 | Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-12 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-06-12 | A | 4,500 | 21 | 96,210 | Common | Form 4 ↗ |
| Jula Inrig | CHIEF MEDICAL OFFICER | 2026-06-22 | D | 468 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jula Inrig | OPTION | 2025-01-31 | — | — | 100,000 | — | $1,272,840 |
| Eric Dube | RSU | 2025-01-31 | — | — | 130,000 | — | 2,659,800 |
| Jula Inrig | PSU | 2025-01-31 | — | 7,000 | — | 14,000 | 143,220 |
| William Rote | PSU | 2025-01-31 | — | 7,000 | — | 14,000 | 143,220 |
| Jula Inrig | RSU | 2025-01-31 | — | — | 30,000 | — | 613,800 |
| Christopher Cline | OPTION | 2025-01-31 | — | — | 58,000 | — | 738,247 |
| William Rote | OPTION | 2025-01-31 | — | — | 58,000 | — | 738,247 |
| Peter Heerma | PSU | 2025-01-31 | — | 7,000 | — | 14,000 | 143,220 |
| Christopher Cline | RSU | 2025-01-31 | — | — | 21,500 | — | 439,890 |
| Eric Dube | PSU | 2025-01-31 | — | 32,000 | — | 64,000 | 654,720 |
| Eric Dube | OPTION | 2025-01-31 | — | — | 260,000 | — | 3,309,384 |
| Peter Heerma | RSU | 2025-01-31 | — | — | 21,500 | — | 439,890 |
| William Rote | RSU | 2025-01-31 | — | — | 21,500 | — | 439,890 |
| Christopher Cline | PSU | 2025-01-31 | — | 7,000 | — | 14,000 | 143,220 |
| Peter Heerma | OPTION | 2025-01-31 | — | — | 58,000 | — | 738,247 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jula Inrig | $613,800 | $143,220 | $1,272,840 | 7.1% |
| Eric Dube | 2,659,800 | 654,720 | 3,309,384 | 9.9% |
| William Rote | 439,890 | 143,220 | 738,247 | 10.8% |
| Christopher Cline | 439,890 | 143,220 | 738,247 | 10.8% |
| Peter Heerma | 439,890 | 143,220 | 738,247 | 10.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Eric Dube | RSU | 32,000 | — | $1,222,720 |
| Eric Dube | RSU | 45,000 | — | 1,719,450 |
| William Rote | Option | 820 | 27.5 | — |
| Peter Heerma | Option | 58,000 | 20.46 | — |
| William Rote | RSU | 2,460 | — | 93,997 |
| Christopher Cline | RSU | 18,750 | — | 716,438 |
| Eric Dube | Option | 260,000 | 20.46 | — |
| Eric Dube | RSU | 101,250 | — | 3,868,763 |
| Eric Dube | RSU | 48,750 | — | 1,862,738 |
| Eric Dube | Option | 70,417 | 22.4 | — |
| Eric Dube | RSU | 18,924 | — | 723,086 |
| Peter Heerma | RSU | 18,750 | — | 716,438 |
| Christopher Cline | Option | 365 | 27.5 | — |
| Peter Heerma | RSU | 7,000 | — | 267,470 |
| Jula Inrig | Option | 14,761 | 22.4 | — |
| William Rote | RSU | 4,920 | — | 187,993 |
| William Rote | RSU | 18,750 | — | 716,438 |
| William Rote | Option | 14,761 | 22.4 | — |
| Christopher Cline | RSU | 4,920 | — | 187,993 |
| Christopher Cline | Option | 58,000 | 20.46 | — |
| Peter Heerma | Option | 14,761 | 22.4 | — |
| Peter Heerma | RSU | 10,125 | — | 388,876 |
| Christopher Cline | RSU | 8,500 | — | 324,785 |
| William Rote | RSU | 10,125 | — | 386,876 |
| Peter Heerma | RSU | 21,500 | — | 821,515 |
| Jula Inrig | RSU | 7,000 | — | 267,470 |
| Eric Dube | RSU | 9,462 | — | 361,543 |
| Christopher Cline | RSU | 2,188 | — | 83,603 |
| Christopher Cline | RSU | 7,000 | — | 267,470 |
| William Rote | RSU | 8,500 | — | 324,785 |
| Jula Inrig | RSU | 18,750 | — | 716,438 |
| William Rote | RSU | 21,500 | — | 821,515 |
| Christopher Cline | RSU | 21,500 | — | 821,515 |
| Eric Dube | RSU | 130,000 | — | 4,967,300 |
| Jula Inrig | RSU | 8,500 | — | 324,785 |
| William Rote | RSU | 7,000 | — | 267,470 |
| Christopher Cline | Option | 33,855 | 8.93 | — |
| Christopher Cline | Option | 9,000 | 28.06 | — |
| Eric Dube | Option | 3,533 | 27.5 | — |
| Eric Dube | Option | 187,500 | 8.93 | — |
| Jula Inrig | Option | 47,396 | 8.93 | — |
| Peter Heerma | Option | 33,855 | 8.93 | — |
| Christopher Cline | Option | 14,761 | 22.4 | — |
| Jula Inrig | RSU | 10,125 | — | 386,876 |
| Peter Heerma | RSU | 4,920 | — | 187,993 |
| Peter Heerma | RSU | 8,500 | — | 324,785 |
| William Rote | Option | 33,855 | 8.93 | — |
| William Rote | Option | 58,000 | 20.46 | — |
| Christopher Cline | RSU | 1,250 | — | 47,763 |
| Christopher Cline | Option | 417 | 28.55 | — |
| Jula Inrig | RSU | 30,000 | — | 1,146,300 |
| Christopher Cline | RSU | 10,125 | — | 386,876 |
| Jula Inrig | RSU | 5,000 | — | 191,050 |
| Peter Heerma | RSU | 2,460 | — | 93,997 |
| Peter Heerma | Option | 820 | 27.5 | — |
| Christopher Cline | RSU | 125 | — | 4,776 |
| Jula Inrig | Option | 1,667 | 30.6 | — |
| Jula Inrig | Option | 100,000 | 20.46 | — |
The Company's compensation program for executive officers consists of: base salary, cash incentives, long-term equity awards, retirement benefits as provided under the Company's 401(k) plan, severance agreements and other benefits. The Company uses the peer group established by the Compensation Committee as a guideline for establishing base salaries, cash incentives and long-term equity award components of compensation.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 73,711,670 | 2,073,324 | 33,152 | 97.22% | Passed |
| 2025 | 2025-05-15 | 71,929,269 | 2,677,694 | 48,048 | 96.35% | Passed |
| 2024 | 2024-05-08 | 55,789,526 | 2,854,506 | 42,079 | 95.06% | Passed |
| 2023 | 2023-05-17 | 56,251,737 | 5,363,550 | 26,929 | 91.26% | Passed |
| 2022 | 2022-05-11 | 34,854,828 | 15,838,930 | 1,486 | 68.75% | Passed |
| 2021 | 2021-05-14 | 51,280,405 | 973,713 | 90,105 | 97.97% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-19 | 97.22%a |
| 2025 | 2025-05-15 | 96.35%b |
| 2024 | 2024-05-08 | 95.06%c |
a. Approved under the standard stated in the filing — “For Proposal 4, abstentions will be counted towards the vote total, and will have the same effect as votes "Against" each of the proposed voting frequencies.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposals 2, 3 and 4 and will have the same effect as "Against" votes.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as "Against" votes.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | $8,457,151 |
| Median employee compensation | $364,999 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gary LyonsIndependent · Audit | $88,750 | $137,475 | $412,425 | $0 | $0 | $638,650 |
| Timothy CoughlinIndependent · Compensation · Audit | 79,375 | 137,475 | 412,425 | 0 | 0 | 629,275 |
| Jeffrey MecklerIndependent · Audit | 72,000 | 137,475 | 412,425 | 0 | 0 | 621,900 |
| Roy BaynesIndependent · Science & Medical Technology (Chair) · Nominating/Corporate Governance | 70,000 | 137,475 | 412,425 | 0 | 0 | 619,900 |
| John A. OrwinIndependent · Compensation (Chair) | 68,750 | 137,475 | 412,425 | 0 | 0 | 618,650 |
| Suzanne BruhnIndependent · Compensation | 66,875 | 137,475 | 412,425 | 0 | 0 | 616,775 |
| Sandra PooleIndependent · Audit (Chair) | 62,500 | 137,475 | 412,425 | 0 | 0 | 612,400 |
| Ron SquarerIndependent · Nominating/Corporate Governance | 60,000 | 137,475 | 412,425 | 0 | 0 | 609,900 |
| Ruth Williams-BrinkleyIndependent · Compensation · Nominating/Corporate Governance (Chair) | 59,375 | 137,475 | 412,425 | 0 | 0 | 609,275 |
| Eric DubeEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $549,900 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $627,625 |
| Equity awards (grant-date value) | $1,237,275 |
| All other compensation | $0 |
| Total cost of the board | $1,864,900 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Travere Therapeutics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Travere Therapeutics, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Rhythm Pharmaceuticals | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | Supernus Pharmaceuticals | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 4 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 5 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 6 | Ligand Pharmaceuticals | 2025 | Todd Davis | 724,500 | 5,520,493 | 4,441,120 | 764,400 | 11,472,095 |
| 7 | Ultragenyx Pharmaceutical | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 8 | Vericel | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 9 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 10 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 11 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 12 | Harmony Biosciences | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 13 | Phathom Pharmaceuticals | 2025 | Steven Basta | 525,000 | 1,986,600 | 3,983,144 | 455,701 | 6,968,070 |
| 14 | Xeris Biopharma | 2025 | John Shannon | 742,334 | 2,848,000 | 838,615 | 607,971 | 5,042,584 |
| 15 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 16 | Ironwood Pharmaceuticals | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 17 | Collegium Pharmaceutical | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Coherus BioSciences | not disclosed | Options 100 | not disclosed | Aon |
| Collegium Pharmaceutical | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics | 100% | not disclosed | not disclosed | not disclosed |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Harmony Biosciences | 100% | not disclosed | not disclosed | Pay Governance |
| Ironwood Pharmaceuticals | 100% | PSU 50 · RSU 50 | Yes — relative total stockholder return (rTSR) | Alpine Rewards LLC |
| Ligand Pharmaceuticals | 150% | Options 44 · PSU 31 · RSU 25 | No | Aon (Talent Solutions practice) |
| Mirum Pharmaceuticals | 200% | not disclosed | No | Alpine Rewards |
| Pacira BioSciences | 90% | RSU 100 | No | Aon (Aon plc, Human Capital Solutions practice) |
| Phathom Pharmaceuticals | 124% | not disclosed | No | Pay Governance LLC |
| PTC Therapeutics | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Rhythm Pharmaceuticals | 120% | Options 50 · RSU 50 | No | Pay Governance LLC |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions practice) |
| Ultragenyx Pharmaceutical | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vericel | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
| Xeris Biopharma | 125% | not disclosed | not disclosed | Aon Consulting, Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Eric Dube | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Summary Compensation Table”. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 2 | Section 01, Jula Inrig | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Summary Compensation Table”. As printed: 3,041,632. Filing ↗machine: span 586826–586835 |
| 3 | Section 01, Peter Heerma | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Summary Compensation Table”. As printed: 2,261,751. Filing ↗machine: span 577253–577262 |
| 4 | Section 01, William Rote | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Summary Compensation Table”. As printed: 2,256,465. Filing ↗machine: span 595775–595784 |
| 5 | Section 01, Christopher Cline | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Summary Compensation Table”. As printed: 2,250,914. Filing ↗machine: span 568312–568321 |
| 6 | Section 03, Jula Inrig OPTION | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r16 · c27 · span 658608–658617 |
| 7 | Section 03, Eric Dube RSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r6 · c26 · span 630213–630222 |
| 8 | Section 03, Jula Inrig PSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r17 · c26 · span 661186–661193 |
| 9 | Section 03, William Rote PSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r21 · c26 · span 673435–673442 |
| 10 | Section 03, Jula Inrig RSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r18 · c26 · span 663419–663426 |
| 11 | Section 03, Christopher Cline OPTION | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r8 · c27 · span 635525–635532 |
| 12 | Section 03, William Rote OPTION | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r20 · c27 · span 670134–670141 |
| 13 | Section 03, Peter Heerma PSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r13 · c26 · span 650340–650347 |
| 14 | Section 03, Christopher Cline RSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r10 · c26 · span 640334–640341 |
| 15 | Section 03, Eric Dube PSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r5 · c26 · span 627254–627261 |
| 16 | Section 03, Eric Dube OPTION | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r4 · c27 · span 623950–623959 |
| 17 | Section 03, Peter Heerma RSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r14 · c26 · span 653298–653305 |
| 18 | Section 03, William Rote RSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r22 · c26 · span 676393–676400 |
| 19 | Section 03, Christopher Cline PSU | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r9 · c26 · span 638101–638108 |
| 20 | Section 03, Peter Heerma OPTION | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r8 · c16 · span 576278–576285 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗machine: span 1020639–1020641 |
| 22 | Section 08, Gary Lyons | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 638,650. Filing ↗machine: t39 · r5 · c15 · span 1125703–1125710 |
| 23 | Section 08, Timothy Coughlin | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 629,275. Filing ↗machine: t39 · r4 · c15 · span 1123004–1123011 |
| 24 | Section 08, Jeffrey Meckler | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 621,900. Filing ↗machine: t39 · r6 · c15 · span 1128407–1128414 |
| 25 | Section 08, Roy Baynes | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 619,900. Filing ↗machine: t39 · r2 · c15 · span 1117572–1117579 |
| 26 | Section 08, John A. Orwin | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 618,650. Filing ↗machine: t39 · r7 · c15 · span 1131106–1131113 |
| 27 | Section 08, Suzanne Bruhn | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 616,775. Filing ↗machine: t39 · r3 · c15 · span 1120303–1120310 |
| 28 | Section 08, Sandra Poole | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 612,400. Filing ↗machine: t39 · r8 · c15 · span 1133807–1133814 |
| 29 | Section 08, Ron Squarer | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 609,900. Filing ↗machine: t39 · r9 · c15 · span 1136507–1136514 |
| 30 | Section 08, Ruth Williams-Brinkley | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 609,275. Filing ↗machine: t39 · r10 · c15 · span 1139218–1139225 |
| 31 | Section 08, Eric Dube | DEF 14A | 2026-04-06 | 0001438533-26-000027 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 02, Roy Baynes 2026-04-06 | Form 4 | 2026-04-07 | 0001680739-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Roy Baynes 2026-04-06 | Form 4 | 2026-04-07 | 0001680739-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Roy Baynes 2026-04-06 | Form 4 | 2026-04-07 | 0001680739-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Christopher Cline 2026-04-13 | Form 4 | 2026-04-15 | 0001943192-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Jula Inrig 2026-04-13 | Form 4 | 2026-04-15 | 0001902368-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Christopher Cline 2026-04-13 | Form 4 | 2026-04-15 | 0001943192-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Eric Dube 2026-04-13 | Form 4 | 2026-04-15 | 0001763494-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Jula Inrig 2026-04-13 | Form 4 | 2026-04-15 | 0001902368-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Jula Inrig 2026-04-13 | Form 4 | 2026-04-15 | 0001902368-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Peter Heerma 2026-04-13 | Form 4 | 2026-04-15 | 0001789617-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, William Rote 2026-04-13 | Form 4 | 2026-04-15 | 0001698262-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Eric Dube 2026-04-13 | Form 4 | 2026-04-15 | 0001763494-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Eric Dube 2026-04-13 | Form 4 | 2026-04-15 | 0001763494-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Peter Heerma 2026-04-13 | Form 4 | 2026-04-15 | 0001789617-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Eric Dube 2026-04-13 | Form 4 | 2026-04-15 | 0001763494-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Christopher Cline 2026-04-13 | Form 4 | 2026-04-15 | 0001943192-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Elizabeth E. Reed 2026-04-13 | Form 4 | 2026-04-15 | 0001283303-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Christopher Cline 2026-04-13 | Form 4 | 2026-04-15 | 0001943192-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Christopher Cline 2026-04-13 | Form 4 | 2026-04-15 | 0001943192-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Gary Lyons 2026-04-14 | Form 4 | 2026-04-16 | 0001123343-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Gary Lyons 2026-04-14 | Form 4 | 2026-04-16 | 0001123343-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Gary Lyons 2026-04-14 | Form 4 | 2026-04-16 | 0001123343-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Roy Baynes 2026-04-14 | Form 4 | 2026-04-16 | 0001680739-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Sandra Calvin 2026-04-14 | Form 4 | 2026-04-16 | 0001882909-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, William Rote 2026-04-22 | Form 4 | 2026-04-23 | 0001698262-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Roy Baynes 2026-05-01 | Form 4 | 2026-05-04 | 0001680739-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Roy Baynes 2026-05-01 | Form 4 | 2026-05-04 | 0001680739-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Roy Baynes 2026-05-01 | Form 4 | 2026-05-04 | 0001680739-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Christopher Cline 2026-05-04 | Form 4 | 2026-05-06 | 0001943192-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, William Rote 2026-05-04 | Form 4 | 2026-05-06 | 0001698262-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Peter Heerma 2026-05-04 | Form 4 | 2026-05-06 | 0001789617-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Peter Heerma 2026-05-04 | Form 4 | 2026-05-06 | 0001789617-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Eric Dube 2026-05-04 | Form 4 | 2026-05-06 | 0001763494-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Christopher Cline 2026-05-04 | Form 4 | 2026-05-06 | 0001943192-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, William Rote 2026-05-04 | Form 4 | 2026-05-06 | 0001698262-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Elizabeth E. Reed 2026-05-04 | Form 4 | 2026-05-06 | 0001283303-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Eric Dube 2026-05-04 | Form 4 | 2026-05-06 | 0001763494-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Eric Dube 2026-05-04 | Form 4 | 2026-05-06 | 0001763494-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Christopher Cline 2026-05-04 | Form 4 | 2026-05-06 | 0001943192-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Peter Heerma 2026-05-04 | Form 4 | 2026-05-06 | 0001789617-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Jeffrey Meckler 2026-05-04 | Form 4 | 2026-05-06 | 0001506916-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Jeffrey Meckler 2026-05-04 | Form 4 | 2026-05-06 | 0001506916-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Jeffrey Meckler 2026-05-04 | Form 4 | 2026-05-06 | 0001506916-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, William Rote 2026-05-04 | Form 4 | 2026-05-06 | 0001698262-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, William Rote 2026-05-04 | Form 4 | 2026-05-06 | 0001698262-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Jula Inrig 2026-05-04 | Form 4 | 2026-05-06 | 0001902368-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Peter Heerma 2026-05-04 | Form 4 | 2026-05-06 | 0001789617-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Eric Dube 2026-05-04 | Form 4 | 2026-05-06 | 0001763494-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Christopher Cline 2026-05-04 | Form 4 | 2026-05-06 | 0001943192-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Christopher Cline 2026-05-04 | Form 4 | 2026-05-06 | 0001943192-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Roy Baynes 2026-05-05 | Form 4 | 2026-05-06 | 0001680739-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Roy Baynes 2026-05-05 | Form 4 | 2026-05-06 | 0001680739-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Roy Baynes 2026-05-05 | Form 4 | 2026-05-06 | 0001680739-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Timothy Coughlin 2026-05-15 | Form 4 | 2026-05-19 | 0001376043-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Roy Baynes 2026-05-19 | Form 4 | 2026-05-21 | 0001680739-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Suzanne Bruhn 2026-05-19 | Form 4 | 2026-05-21 | 0001517790-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, John A. Orwin 2026-05-19 | Form 4 | 2026-05-21 | 0001477384-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Brinkley Ruth Williams 2026-05-19 | Form 4 | 2026-05-21 | 0001344381-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Sandra Poole 2026-05-19 | Form 4 | 2026-05-21 | 0001619622-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Roy Baynes 2026-05-19 | Form 4 | 2026-05-21 | 0001680739-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Timothy Coughlin 2026-05-19 | Form 4 | 2026-05-21 | 0001376043-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Gary Lyons 2026-05-19 | Form 4 | 2026-05-21 | 0001123343-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Gary Lyons 2026-05-19 | Form 4 | 2026-05-21 | 0001123343-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Jeffrey Meckler 2026-05-19 | Form 4 | 2026-05-21 | 0001506916-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Sandra Poole 2026-05-19 | Form 4 | 2026-05-21 | 0001619622-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Brinkley Ruth Williams 2026-05-19 | Form 4 | 2026-05-21 | 0001344381-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Jeffrey Meckler 2026-05-19 | Form 4 | 2026-05-21 | 0001506916-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Ron Squarer 2026-05-19 | Form 4 | 2026-05-21 | 0001454001-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Suzanne Bruhn 2026-05-19 | Form 4 | 2026-05-21 | 0001517790-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Ron Squarer 2026-05-19 | Form 4 | 2026-05-21 | 0001454001-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, John A. Orwin 2026-05-19 | Form 4 | 2026-05-21 | 0001477384-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Timothy Coughlin 2026-05-19 | Form 4 | 2026-05-21 | 0001376043-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Roy Baynes 2026-06-12 | Form 4 | 2026-06-16 | 0001680739-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Timothy Coughlin 2026-06-12 | Form 4 | 2026-06-16 | 0001376043-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Roy Baynes 2026-06-12 | Form 4 | 2026-06-16 | 0001680739-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Timothy Coughlin 2026-06-12 | Form 4 | 2026-06-16 | 0001376043-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Timothy Coughlin 2026-06-12 | Form 4 | 2026-06-16 | 0001376043-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Roy Baynes 2026-06-12 | Form 4 | 2026-06-16 | 0001680739-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Jula Inrig 2026-06-22 | Form 4 | 2026-06-22 | 0001902368-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 06, 2026 vote | Form 8-K | 2026-05-21 | 0001438533-26-000046 | Item 5.07 · say-on-pay result. As reported: 97.22% (votes for as printed: 73,711,670). Filing ↗ |
| 153 | Section 06, 2025 vote | Form 8-K | 2025-05-16 | 0001438533-25-000034 | Item 5.07 · say-on-pay result. As reported: 96.35% (votes for as printed: 71,929,269). Filing ↗ |
| 154 | Section 06, 2024 vote | Form 8-K | 2024-05-13 | 0001438533-24-000022 | Item 5.07 · say-on-pay result. As reported: 95.06% (votes for as printed: 55,789,526). Filing ↗ |
| 155 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 156 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 157 | Section 09b board cost (computed) | Computed | — | computed | Cash 627,625 + equity 1,237,275 + all other 0 = 1,864,900, summed across the director compensation table rows.machine: formula: Σ = 1,864,900 |
| 158 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 159 | Rhythm Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 160 | Supernus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 161 | Corcept Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 162 | Pacira BioSciences, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 163 | Ligand Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-21 | 0000886163-26-000021 | CEO total compensation as printed in Ligand Pharmaceuticals's own proxy. As printed: 11,472,095. Filing ↗machine: span 722741–722751 |
| 164 | Ultragenyx Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 165 | Vericel, Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 166 | Mirum Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 167 | Travere Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 168 | Dynavax Technologies, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗ |
| 169 | Harmony Biosciences, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 170 | Phathom Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144570 | CEO total compensation as printed in Phathom Pharmaceuticals's own proxy. As printed: 6,968,070. Filing ↗machine: r2 · c21 · span 619155–619164 |
| 171 | Xeris Biopharma, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001867096-26-000021 | CEO total compensation as printed in Xeris Biopharma's own proxy. As printed: 5,042,584. Filing ↗machine: r3 · c42 · span 463532–463541 |
| 172 | Coherus BioSciences, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045251 | CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. Filing ↗machine: t112 · r5 · c14 · span 540087–540096 |
| 173 | Ironwood Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191 |
| 174 | Collegium Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical's own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 175 | Section 10a, Vericel reciprocity | DEF 14A | — | 0001308179-26-000094 | Vericel names Travere Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 176 | Section 10a, Harmony Biosciences reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 177 | Section 10a, Collegium Pharmaceutical reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 178 | Section 10a, Dynavax Technologies reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies names Travere Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 179 | Section 10a, Rhythm Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals names Travere Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 180 | Section 10a, Xeris Biopharma reciprocity | DEF 14A | — | 0001867096-26-000021 | Xeris Biopharma names Travere Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 181 | Section 10a, Coherus BioSciences reciprocity | DEF 14A | — | 0001104659-26-045251 | Coherus BioSciences's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 182 | Section 10a, Ligand Pharmaceuticals reciprocity | DEF 14A | — | 0000886163-26-000021 | Ligand Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 183 | Section 10a, Pacira BioSciences reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences names Travere Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 184 | Section 10a, Supernus Pharmaceuticals reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 185 | Section 10a, Mirum Pharmaceuticals reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 186 | Section 10a, Ultragenyx Pharmaceutical reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |
| 187 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include Travere Therapeutics, Inc.. Filing ↗ |